AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00829114
Drug: ETHINYL ESTRADIOL AND LEVOGESTREL
RxNorm normalized name: desogestrel / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
Trial: NCT04532775
Drug: saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for intravenous and epidural injection
Trial: NCT01939184
Drug: WC3055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5, 25, 50 or 75 mg dose
Trial: NCT01257672
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04638426
Drug: HL237 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day
Trial: NCT04638426
Drug: Placebo of HL237 tablet
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of HL237, twice a day
Trial: NCT00278746
Drug: Zinc and ORS
RxNorm normalized name: zinc gluconate Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Government and private providers and village health workers were trained to prescribe zinc and ORS for use in diarrheal episodes in 1 month to 5 years old children in intervention communities
Trial: NCT02183246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03722433
Drug: Placebo and sequential therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo without Vigiis 101-LAB component
Trial: NCT03772262
Drug: Rosuvastatin Oral Tablet
RxNorm normalized name: rosuvastatin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT00703924
Drug: WR 279,396
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A topical cream containing 15% paromomycin and 0.5% gentamicin. Approximately 0.0005 mL per mm2 of skin lesion
Trial: NCT00703924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream vehicle. Approximately 0.0005 mL per mm2 of skin lesion
Trial: NCT04205682
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules administered BD for 5 days
Trial: NCT00051909
Drug: LY451395
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02199925
Drug: Gammaplex 5%
RxNorm normalized name: Gammaplex 5% 5g Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01736670
Drug: Alcohol spray
RxNorm normalized name: Isopropyl Alcohol 70% Topical application Spray [ALCOHOL SPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00852787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously one time
Trial: NCT04044339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to be administered orally
Trial: NCT01066741
Drug: Homeodent®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-minute mouthwash with 5 ml of solution diluted in 125 ml of water, 3 times per day after meals and tooth brushing.
Trial: NCT00533299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos will start from seven days before day 1 of chemotherapy until the end of the sixth course. Placebo tablets will be administered in an identical form that experimental drugs.
Trial: NCT01400568
Drug: LPS challenge with nebulized LPS
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20,000 EU of Clinical Center Reference Endotoxine (CCRE) will be applied by an AKITA® Jet Nebulizer under the constant supervision of the site staff.
Trial: NCT01565681
Drug: ASP1240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion
Trial: NCT01565681
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion
Trial: NCT00589771
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Saccharomyces boulardii one capsule 250mg TDS for 6 weeks~2. Ispaghula husk 1 Tsf daily after dinner for six weeks
Trial: NCT00589771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Cap Placebo TDS for six weeks~2. Ispaghula husk 1 Tsf daily after dinner for six weeks
Trial: NCT00776711
Drug: Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01729156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets twice daily in 3 months
Trial: NCT04082715
Drug: carbidopa/levodopa and celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every patient of this arm will get one bottle of carbidopa/levodopa and one bottle of celecoxib. At treatment initiation, Carbidopa/Levodopa will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with carbidopa/levodopa twice daily for 3 days and then once daily for 3 days before discontinuing it completely.Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
Trial: NCT04082715
Drug: placebo1 and celecoxib
RxNorm normalized name: amlodipine and celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every patient of this arm will get one bottle of placebo1 and one bottle of celecoxib. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
Trial: NCT04082715
Drug: placebo1 and placebo2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every patient of this arm will get one bottle of placebo1 and one bottle of placebo2. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. placebo2 will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
Trial: NCT01726582
Drug: Milestone 1: Targeted chemotherapy prior to surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
Trial: NCT01726582
Drug: Milestone 3: Targeted chemotherapy prior to surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
Trial: NCT01726582
Drug: Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A biopsy of the borderline tumor does not provide a molecular profile that can be used to target treatment. The treatment will be standard FOLFIRINOX chemotherapy regimen.
Trial: NCT01726582
Drug: Milestone 5: Targeted chemotherapy after surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
Trial: NCT01726582
Drug: Milestone 8: Targeted chemotherapy after surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
Trial: NCT01247168
Drug: AZD2461
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsules, continuous dosing and intermittent dosing
Trial: NCT00551109
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, oral administration, once daily for 8 weeks
Trial: NCT02057172
Drug: HM11260C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
Trial: NCT02057172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03329092
Drug: ATM-AVI
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (Creatinine clearance \> 50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI~(Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI
Trial: NCT04412772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
Trial: NCT02693613
Drug: ASP1517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02693613
Drug: Kremezin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04426955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT00181584
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given intravenously once.
Trial: NCT00783614
Drug: Antiretroviral therapy (ART)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to start ART immediately or defer use for 1 month
Trial: NCT02113241
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, 10 mg, one per day before breakfast during 90 days.
Trial: NCT01915173
Drug: Supplement
RxNorm normalized name: fat supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C
Trial: NCT03025399
Drug: Tangwang prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A kind of Granule(Tangwang prescription) was composition by five Chinese herbal medicines, every bag has 4.87g granules.
Trial: NCT03025399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a simulated drug of tangwang prescription,included weight, appearance, colour, taste,smell and solubility.
Trial: NCT01915173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose tablets
Trial: NCT00830466
Drug: Laser and rapamycin versus laser alone
RxNorm normalized name: ELECTRODE GEL,LASER TOUCH ONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser and rapamycin versus laser alone
Trial: NCT00847886
Drug: LX3305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral intake of LX3305 for 14 days.
Trial: NCT00847886
Drug: LX3305 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo dosing with daily oral intake for 14 days.
Trial: NCT00847886
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once weekly stable-dose methotrexate.
Trial: NCT01517555
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
Trial: NCT00345865
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NHL with radiation: Cyclophosphamide 60 mg/kg intravenous (IV) over two hours daily x 2 days.~HL without radiation: Cyclophosphamide, Days - 6 through -3, 1.5 gm/m\^2 over 2 hours daily x 4 days.~Cyclophosphamide will be dosed based on actual body weight (ABW) unless the patient is 20% or more of ideal body weight (IBW). If more than 20% of ideal body weight, an adjusted ideal body weight (AIBW) will be used for dosing.
Trial: NCT03665493
Drug: PD patients H&Y=1.5-2 Medications ON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
Trial: NCT03665493
Drug: PD patients H&Y=1.5-2 Medications OFF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
Trial: NCT03665493
Drug: PD patients H&Y=3 Medications OFF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
Trial: NCT03665493
Drug: PD patients H&Y=3 Medications ON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
Trial: NCT00492895
Drug: Discontinuation of Azathioprin
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Discontinuation of Azathioprin
Trial: NCT04311567
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Open-label methotrexate for 48 weeks. All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
Trial: NCT00621010
Drug: CTS21166 (ZPQ-21166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: (7.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 2: (22.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 3: (45 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 4: (90 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 5: (150 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 6: (225 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days,proceed to Part B.~Cohort 7: (225 mg): Up to 10 subjects, open label, 3 hour infusion
Trial: NCT01807091
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive outpatient induction chemotherapy
Trial: NCT03382262
Drug: FX006 32 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release 32 mg FX006 IA injection
Trial: NCT03382262
Drug: TAcs 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release 40mg TAcs IA injection
Trial: NCT03641794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03425643
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline by IV infusion Q3W, given on cycle day 1.
Trial: NCT02916901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04613271
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 500 mg once a day for 5 days.
Trial: NCT01407406
Drug: BIIB023 - high dose IV Dose
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01464125
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin capsules 250 mg x 3 twelve-hourly for three days
Trial: NCT02502162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill
Trial: NCT04213924
Drug: 5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously, 30 min before the ESWL procedure.
Trial: NCT00498134
Drug: Triple therapy for H. pylori infection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00498134
Drug: Cox-2 inhibitor
RxNorm normalized name: COX-2 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04376970
Drug: FLUCON®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug was prescribed monthly according to the predefined regimen. It was not namely specefied in the prescription and was delivered by the hospital pharmacy according to the randomisation list.The subjects were masked to the contents and were instructed to return the empty tubes on monthly visit, wherein 1 pack of topical treatment was provided to them. Neither the patient nor the ophthalmologist knew the allocated treatment. No other medication was allowed during the trial. Duration of the whole regimen was six months. The study included an extra month after the end of the regimen. It was called  wash-out . Patients who had less than one month of treatment or an uncontrolled treatment side effect or who presented a degenerative iron line were excluded from the rest of the regimen.
Trial: NCT03793361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression~Provided by BAYER
Trial: NCT03856827
Drug: IW-6463
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IW-6463 Tablet
Trial: NCT03856827
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo Tablet
Trial: NCT03523702
Drug: PembroRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients whose tumors are found to have high (≥ 50%) PD-L1 expression will automatically be placed in the PembroRT group. These patients will receive three intravenous treatments with pembrolizumab, followed by four weeks of daily radiotherapy, followed by up to 12 more treatments with pembrolizumab. Pembrolizumab is given as an intravenous infusion once every three weeks. This treatment course will last, in total, up to one year.~Patients whose tumors are found to have low (\< 50%) PD-L1 will be treated with a standard-o-care regimen and not be a part of this clinical trial.
Trial: NCT00795236
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One 0.5 mg tablet of melatonin will be taken by subjects who are free-running and willing to enter the intervention phase of the study. These subjects will take melatonin until entrainment status is confirmed or throughout the duration of the study.
Trial: NCT02549001
Drug: P-3058 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02549001
Drug: vehicle of P-3058 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01413828
Drug: concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
Trial: NCT01413828
Drug: sequential
RxNorm normalized name: TABLET, SEQUENTIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab will be administered sequentially to any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
Trial: NCT03372447
Drug: Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg.
Trial: NCT01022138
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide
Trial: NCT01010971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo HFA Nasal Aerosol once daily